Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Fortrea Holdings's Revenue for the
three
months ended in Mar. 2026 was €551 Mil. Fortrea Holdings's average Accounts Receivable for the
three
months ended in Mar. 2026 was €104 Mil.
Hence, Fortrea Holdings's Receivables Turnover for the
three
months ended in Mar. 2026 was 5.28.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Fortrea Holdings Receivables Turnover Related Terms
Fortrea Holdings Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Fortrea Holdings's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:K67 vs SNDX, KARD, OCUL: Receivables Turnover Comparison
For the Biotechnology subindustry, Fortrea Holdings's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fortrea Holdings Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fortrea Holdings's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Fortrea Holdings's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fortrea Holdings (FRA:K67) has a Receivables Turnover of 5.28 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Fortrea Holdings and its competitors. According to the industry distribution chart, Fortrea Holdings ranks #98 out of 841 companies in the Biotechnology industry, placing it in the top 11.7%.
Is Fortrea Holdings' Receivables Turnover too high?
Fortrea Holdings' current Receivables Turnover is 5.28. The Biotechnology industry median Receivables Turnover is 5.27. Fortrea Holdings' value of 5.28 is 0.2% above this industry median. Based on the distribution chart, Fortrea Holdings ranks #98 out of 841 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Fortrea Holdings has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fortrea Holdings' Receivables Turnover compare to SNDX and KARD?
According to the Biotechnology industry distribution chart, Fortrea Holdings ranks #98 out of 841 companies for Receivables Turnover. This places Fortrea Holdings in the top 12% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.27. Fortrea Holdings' value of 5.28 is 0.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fortrea Holdings's current Receivables Turnover of 5.28 is 0.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Fortrea Holdings and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fortrea Holdings's current Receivables Turnover is 5.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortrea Holdings stock overvalued right now?
Based on GuruFocus' analysis, Fortrea Holdings (FRA:K67) is currently considered Fairly Valued. The stock's GF Value™ is €15.64, compared to a current price of €16.80 — trading 7.4% above its estimated fair value. The current Receivables Turnover is 5.28 and 0.2% above the Biotechnology industry median of 5.27. Fortrea Holdings' overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Fortrea Holdings (FRA:K67), the current Receivables Turnover is 5.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fortrea Holdings (FRA:K67) Overvalued in 2026?
Based on GuruFocus' analysis, Fortrea Holdings stock appears to be overvalued.
The current stock price of €16.80 is trading 7.4% above its estimated GF Value™ of €15.64.
GuruFocus considers Fortrea Holdings to be Fairly Valued.
Key valuation signals for FRA:K67:
Receivables Turnover: 5.28
GF Value™: €15.64 vs. price of €16.80 (7.4% above fair value)
Industry Position: 0.2% above the Biotechnology median (#98 of 841)
No single metric tells the full story. See the FRA:K67 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
65GF Score
Get the complete analysis for FRA:K67
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:K67 has been successfully added to your 
